Immune checkpoint blockade antibodies that augment the effector T cell activity by blocking inhibitory molecules such as programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have achieved unprecedented advances in numerous cancer types [2]. The gene discussed is PDCD1; the disease is cancer.